Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

March 2021
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities.

With this expansion, AGC Biologics will add two additional floors to the suite and install additional equipment on the current floor, within the campus OpenZone. The new facilities are scheduled to begin full operation in 2022.

Mark Womack
Chief Business Officer, AGC Biologics

I’m very pleased that we’ll be able to offer our current and future cell and gene therapy customers even more of what they need from our Milan facility. This is but one of the important steps we are taking to ensure we keep pace with the evolving needs of the market.

Patricio Massera
Chief Executive Officer, AGC Biologics

This investment is part of our global cell and gene therapy expansion plan in Europe, Asia and the US. All of our innovation and expansion is focused on the needs of our partners and the patients they serve. I look forward to announcing additional expansion plans soon.

The expansion comes less than one year following AGC’s successful acquisition and integration of the former MolMed S.p.A. facilities. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has unique commercial manufacturing experience, with two cell & gene therapy products. AGC Biologics is now one of the very few CDMO’s in the world offering both plasmid production and end-to-end cell and gene therapy services.

Luca Alberici as the New General Manager/Site Head of the Milan, Italy Site

On October 2021 Luca Alberici was named General Manager/Site Head at the Milan, Italy site. He is providing leadership and site management to ensure the continued execution of world-class cell and gene therapy contract development and manufacturing services from the Milan, Italy Site. He will support the continuous growth of the Site while working closely with colleagues in Seattle, Heidelberg and Chiba to ensure the business leverages and integrates AGC Biologics combined global capabilities.


Mr. Alberici holds a PhD and Masters in cellular and molecular biology from Libera Università Vita-Salute San Raffaele, in addition to a Master of Business Administration (MBA) from SDA Bocconi. His rich educational background is complemented by more than 14 years of industry expertise with strategic business development, licensing, project management and intellectual property for large molecule and specialty drug development and commercialization.